Clinical evaluation of cefozopran as treatment for febrile neutropenia

Takashi Saito, Masamichi Hara, Katsuji Shinagawa, Yuichiro Nawa, Koichi Nakase, Makoto Takeuchi, Akira Miyata, Shunnichi Fukuda, Kazutaka Sunami, Kenji Imajoh, Tomofumi Yano, Kensuke Kojima, Takanori Teshima, Nobuharu Fujii, Fumihiko Ishimaru, Kazuma Ikeda, Mine Harada, Mitsune Tanimoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clinical effects and safety of cefozopran (CZOP) were evaluated by the Okayama Bone Marrow Transplantation Group. Twenty-five patients expected to experience febrile neutropenia during induction chemotherapy or consolidation chemotherapy of acute leukemia were enrolled between July 2000 and November 2002. CZOP was administrated by drip infusion at 4g/day bid for a minimum of 3 days. The clinical effects and safety were evaluated in 20 patients with fever of 37.5 degrees C or more from a clinically suspected infection. The underlying disease was acute myeloid leukemia in 17 patients, acute lymphoid leukemia in 1 and acute promyelogeneous leukemia in 1. The complicating infections were sepsis and suspected sepsis. Clinical efficacy was excellent in 11 patients, good in 1, fair in 2 and poor in 6, with an efficacy rate of 60.0%. The efficacy rate in patients whose albumin levels before therapy were less than 3.8 g/dl was 37.5%, whereas the rate in patients whose albumin levels before therapy were between 3.8 g/dl and 5.3 g/dl was 80.0%. The efficacy rate in patients whose neutrophil counts before therapy were less than 100/microliter was 50.0%, whereas the rate in patients whose neutrophil counts after therapy were less than 100/microliter was 53.8%. The efficacy rate in patients whose neutrophil counts both before and after therapy were less than 100/microliter was 37.5%. Side effect of exanthema was observed in 1 patient. These results indicate that CZOP is an effective and safe antibiotic for the treatment of febrile neutropenia in patients with hematological malignancies.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume31
Issue number1
Publication statusPublished - Jan 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical evaluation of cefozopran as treatment for febrile neutropenia'. Together they form a unique fingerprint.

  • Cite this

    Saito, T., Hara, M., Shinagawa, K., Nawa, Y., Nakase, K., Takeuchi, M., Miyata, A., Fukuda, S., Sunami, K., Imajoh, K., Yano, T., Kojima, K., Teshima, T., Fujii, N., Ishimaru, F., Ikeda, K., Harada, M., & Tanimoto, M. (2004). Clinical evaluation of cefozopran as treatment for febrile neutropenia. Gan to kagaku ryoho. Cancer & chemotherapy, 31(1), 61-65.